Advice
In the absence of a submission from the holder of the marketing authorisation:
vismodegib (Erivdege ®) is not recommended for use within NHS Scotland.
Indication under review: treatment of adult patients with:
- symptomatic metastatic basal cell carcinoma
- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice89KB (PDF)
Medicine details
- Medicine name:
- vismodegib (Erivedge)
- SMC ID:
- 924/13
- Indication:
- Treatment of adult patients with: symptomatic metastatic basal cell carcinoma & locally advanced basal cell carcinoma; inappropriate for surgery or radiotherapy
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 October 2013